Adil Daud retweeted
🎊🎊Happy New Year 🎊🎊 May we all have a bright 2023 ahead 💐 @ UAE Sharjah instagram.com/p/Cm1ztPayedvf…
Adil Daud retweeted
Four decades of clinical trials: 14.2 million life-years gained, at $326 per year medicalxpress.com/news/2022-…
Adil Daud retweeted
Countdown to 2023: #JITCTop10 - Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials bit.ly/3DGx2O9 @MartinReck2 @PaulNghiem
Monumental work @jvincentchan @alexis_combes @MaxKrummel @UCSFCancer !! Map of cancer immune archetypes expands, deepens and adds dimension to the(useful) “hot” and “cold” classification
Congrats @alexis_combes 🎉. Happy to see this out in @CellCellPress after 6 years of hard work!
1
Adil Daud retweeted
Replying to @jasonlukemd @DrSapnaPatel @MelanomaReAlli @DrBetofMDPhD @AdilDaud3 @ragikudchadkar @PAscierto @CureMelanoma @Immunocore @UPMCHillmanCC
More good news for #Uvealmelanoma #UM MAPK /FAKi combo study.
ophthalmologytimes.com/view/…
And recent @AACR journal article covering the same topic! This combination approach also decreased the tumor burden in models of uveal melanoma liver metastasis.
Thanks @coughlin582 ! Adding a paper from James Lee and @kickassscience1 declining into the mechanism immunology.sciencemag.org/co…
Liver - unfriendly place for IO therapy. First described by @AdilDaud3 More on mech here.
cancerimmunolres.aacrjournal…
nature.com/articles/s41591-0…
Adil Daud retweeted
Liver - unfriendly place for IO therapy. First described by @AdilDaud3 More on mech here.
cancerimmunolres.aacrjournal…
nature.com/articles/s41591-0… – at Pennsylvania, USA
Adil Daud retweeted
I wrote a review with @jasonlukemd highlighting the responses of #dendriticcells (DC) in cancer @CCR_AACR. We are now beginning to understand critical roles DCs in tumors play in coordinating anti-tumor immune responses.
clincancerres.aacrjournals.o…
Adil Daud retweeted
This!! As a new mom who has been back at academic oncology now for 2 months (sorry I've been slacking on my social media😝)- this is amazing. Any more detail on childcare location @ASCO ? Also PSA for BFing mamas: dl @MAMAVA app, so helpful! #career #mom #ichooseboth
Replying to @EladSharonMD
Children are welcome at #ASCO19. More details are available on our family-friendly services here: fal.cn/AIXr
Adil Daud retweeted
Have a patient with an #EndocrineSideEffect as a result of an #immunotherapy? A nice review of the topic is available here: academic.oup.com/jncics/arti… Authors from @MSKCC_OncoNotes, @theNCI, @LombardiCancer, @DanaFarber, @WeillCornell & others! Coordinated by @NCICTEP_ClinRes!
Adil Daud retweeted
Dhanyawad Rashtrapatiji. Ye shayad peheli baar aisa nyota kisi Rashtrapati ne diya hoga. Mujhe aur mere pariwar ko Maji Rashtrapati Smt. Pratibhatai Patil ne amantrit kiya tha 2010 me. Iska kaaran maine ek dost ko apni kidney daan ki thi. Mera dost muslim tha. Dhanyawad. – at Nagpur, India
Adil Daud retweeted
THREE papers in @NatureMedicine on the unexpected role of Shp2 inhibition in KRAS mutant #LungCancer #PancreaticCancer #GastricCancer
- Shp2inh also bypasses the well known resistance mechanisms to MEKinh
nature.com/articles/s41591-0…
nature.com/articles/s41591-0…
nature.com/articles/s41591-0…
Adil Daud retweeted
Therapeutic developments in #PancreaticCancer: current and future perspectives
nature.com/articles/s41575-0…
I like Figure 1 (I hate the actual survival numbers but it's a succinct reminder of where we stand)
Also the #immunotherapy portion is a mini-review by itself
@NatRevGastroHep
Adil Daud retweeted
I had a lot of fun working with @PD_value on this analysis. It only took us 4 years from concept to publication! clincancerres.aacrjournals.o…
Looking forward to an interview session! @zanubiatshams @GururajRai @tahershams - future of health care in the Middle East teapawt.net/forbesme/status/977837…
Join us on March 31, 2018 as Forbes Middle East gathers industry leaders and regulators from the healthcare industry to examine some of the pressing challenges plaguing healthcare.
#forbesmehealth #healthcare #innovation #investment #Middleeast #forbesme
goo.gl/JSPELH
Adil Daud retweeted
We are thankful to @Drrashidalleem and all delegates for joining us in launching this year's colon #cancer awareness initiative offering #free screenings to our communities in UAE. #ScreenAndSurvive @DHA_Dubai
Excited to kick off colorectal cancer screening campaign @zulekhahosptls. #ColorectalCancer affects women as well as men, is highly curable if detected early and has simple, safe, effective screening tests. teapawt.net/tahershams/status/9734…
Adil Daud retweeted
Excited for next week's IO @marketsmarkets meeting, London events.marketsandmarkets.com…. Gene-based #immunotherapy well represented by $ONCS (DNA), #CureVac (mRNA), @Psioxus (oncolytic), and our #antibodygenetransfer program @LeuvenU. Belgian biotechs presenting: $ABLX $CYAD #iTeos






























